Article Details
Retrieved on: 2024-05-02 15:06:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Silk Road Medical's robust Q1 2024 earnings, highlighting its successful adoption of TCAR in vascular surgery among other procedures for treating carotid artery stenosis, a vascular disease with stroke risks. Market research supports the growing use of their products.
Article found on: www.insidermonkey.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here